HIV Pre-Exposure Prophylaxis.

Infect Dis Clin North Am

Paris Cité University, Paris, France; INSERM UMR 944, Paris, France; Department of Infectious Diseases, Assistance Publique - Hôpitaux de Paris, Hôpitaux Saint Louis et Lariboisière, Paris, France.

Published: September 2024

Pre-exposure prophylaxis (PrEP) of human immunodeficiency virus (HIV) represents the most significant breakthrough in the HIV prevention field over the past decade. PrEP is an effective strategy in preventing the transmission of HIV across all populations, providing high adherence. The current PrEP options include oral daily and on-demand tenofovir-based regimens, long-acting injections of cabotegravir, and a 1-month dapivirine vaginal ring. As a component of a multifaceted prevention approach, extensive deployment of PrEP holds the promise to significantly reduce the global HIV epidemic. Nonetheless, barriers still exist in terms of uptake, adherence, and persistence, while disparities in PrEP accessibility remain a concern.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.idc.2024.04.003DOI Listing

Publication Analysis

Top Keywords

pre-exposure prophylaxis
8
hiv
5
prep
5
hiv pre-exposure
4
prophylaxis pre-exposure
4
prophylaxis prep
4
prep human
4
human immunodeficiency
4
immunodeficiency virus
4
virus hiv
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!